MIMEDX Appoints Doug Rice as Chief Financial Officer
05 7월 2023 - 9:00PM
MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today
announced that it has appointed Doug Rice as the Company’s Chief
Financial Officer, effective today. Pete Carlson, who has served in
that role since March 2020, has resigned as Chief Financial
Officer, also effective today.
Mr. Rice joins MIMEDX after nearly a decade as
the CFO of Orthofix Medical, a leading global spine and orthopedics
company, following the company’s recent merger with SeaSpine. Prior
to Orthofix, Mr. Rice was also CFO at Vision Source, held several
finance leadership roles, including at McAfee and Concentra, and
started his career at PricewaterhouseCoopers. Mr. Rice
is a Certified Public Accountant and received his BBA with honors
and his MBA from Southern Methodist University.
“We are excited to welcome Doug to the MIMEDX
team,” stated Joe Capper, MIMEDX’s Chief Executive Officer. “As a
result of a comprehensive search that yielded a number of highly
qualified candidates, we were able to find a proven leader with a
strong record of commercial success in the healthcare
industry. We are extremely pleased that Doug has agreed
to join the MIMEDX leadership team as we endeavor to take the
Company to new heights.”
“I am delighted to be joining Joe and the
terrific team at MIMEDX, to help drive the continued momentum of
the business,” stated Mr. Rice. “As evidenced by the Company’s
strong start to 2023, I believe MIMEDX, with its market-leading
Wound and Surgical position, is at an inflection point and is
poised to capitalize on several strategic opportunities. I am
looking forward to applying my decades of experience to enhance
this strategic positioning and am grateful for Pete and his team’s
accomplishments that have enabled our growth. I also look forward
to working with the investment community and our other stakeholders
alike in the years to come.”
Inducement Grants
The Company also announced that the Compensation
Committee of the Board of Directors of the Company approved
inducement awards under Nasdaq Listing Rule 5635(c)(4) consisting
of 162,000 performance stock units (“PSUs”), 97,200 restricted
stock units (“RSUs”) and a non-qualified stock option to purchase
94,000 shares of the Company’s common stock (the “Options”) with an
exercise price equal to the closing price per share of the
Company’s common stock as reported on the NASDAQ on July 5, 2023 as
a material inducement to Mr. Rice’s hiring as Chief Financial
Officer of the Company.
The PSUs will vest based on a three year
performance period ending on December 31, 2025 based upon the
achievement of specified performance conditions, subject to
Mr. Rice’s continued employment except in the case of
Mr. Rice’s death or disability. Vesting of PSUs at the target
level (or actual performance, if higher) will accelerate upon a
termination of employment without Cause or a termination by Mr.
Rice for Good Reason within two years following a Change in Control
of the Company occurring prior to the end of the performance period
and while Mr. Rice is in continuous service.
The RSUs will vest over a three year period
following grant, one third each year of the vesting period, subject
to Mr. Rice’s continued employment except in the case of
Mr. Rice’s death or disability. The RSUs will also vest upon a
termination of employment without Cause or a termination of
employment by Mr. Rice for Good Reason within two years following a
Change in Control of the Company occurring prior to the end of the
vesting period and while Mr. Rice is in continuous service.
The Options will vest over a four year period
ending on the fourth anniversary of grant, subject to Mr. Rice’s
continued employment, 25% each year of the performance
period. The Options include a one year post-termination
exercise period, to the extent vested, and will expire on the
seventh anniversary of the grant date. The Options will also vest
upon a termination of employment without Cause or a termination of
employment by Mr. Rice for Good Reason within two years following a
Change in Control of the Company occurring prior to the end of the
vesting period and while Mr. Rice is in continuous service.
The PSUs, RSUs and Options were all granted
outside the terms of the Company’s 2016 Equity and Cash Incentive
Plan and approved by the Company’s Compensation Committee of the
Board of Directors in reliance on the employment inducement
exemption under NASDAQ Listing Rule 5635(c)(4), which requires
public announcement of inducement awards. Pursuant to the
requirements of that rule, the Company is issuing this press
release.
About MIMEDX
MIMEDX is a pioneer and leader focused on
helping humans heal. With more than a decade of helping clinicians
manage chronic and other hard-to-heal wounds, MIMEDX is dedicated
to providing a leading portfolio of products for applications in
the wound care, burn, and surgical sectors of healthcare. The
Company’s vision is to be the leading global provider of healing
solutions through relentless innovation to restore quality of life.
For additional information, please visit www.mimedx.com.
MIMEDX Safe Harbor
Statement
Some of the information and statements contained
in this press release and certain oral statements made from time to
time by representatives of MIMEDX constitute “forward-looking
statements” within the meaning of the Private Securities Litigation
Reform Act of 1995 that do not directly or exclusively relate to
historical facts. Forward-looking statements include
statements regarding our belief that MIMEDX and its market-leading
Wound and Surgical positions is at an inflection point and poised
to capitalize on several strategic opportunities. Additional
forward-looking statements may be identified by words such as
“believe,” “expect,” “may,” “plan,” “goal,” “outlook,” “potential,”
“will,” “preliminary,” and similar expressions, and are based on
management’s current beliefs and expectations. Forward-looking
statements are subject to risks and uncertainties, and the Company
cautions investors against placing undue reliance on such
statements. Actual results may differ materially from those set
forth in the forward-looking statements. These statements are based
on numerous assumptions and involve known and unknown risks,
uncertainties and other factors that could significantly affect our
operations and may cause our actual actions, results, financial
condition, performance or achievements to differ materially from
any future actions, results, financial condition, performance or
achievements expressed or implied by any such forward-looking
statements. Factors that may cause such a difference
include, without limitation, those discussed in the Risk Factors
section of the Company’s most recent annual report and quarterly
reports filed with the Securities and Exchange
Commission. Any forward-looking statements speak only
as of the date of this press release and the Company assumes no
obligation to update any forward-looking statement.
ContactMatt NotarianniInvestor
Relations470-304-7291mnotarianni@mimedx.com
MiMedx (NASDAQ:MDXG)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
MiMedx (NASDAQ:MDXG)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024